Anti-Nitric Oxide Synthase, Inducible antibody, Mouse monoclonal

200

mouse

purified from hybridoma cell culture

primary antibodies

NOS-IN, monoclonal

buffered aqueous solution

~130 kDa

mouse, human, rat, plant

~1.0 mg/mL

flow cytometry: suitable
immunoblotting: 2-4 μg/mL using mouse macrophage RAW 264.7 cell line activated with lipopolysaccharide (LPS) and interferon-γ
immunohistochemistry: 10-20 μg/mL using heat-retrieved formalin-fixed, paraffin-embedded human pancreas sections

IgG1

P35228

dry ice

−20℃

mouse ... Nos2(18126)

Anti-Nitric Oxide Synthase, Inducible antibody, Mouse monoclonal (mouse IgG1 isotype) is derived from the NOS-IN hybridoma, produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mouse. Inducible-type nitric oxide synthase (NOS) of mouse macrophage origin (iNOS) or macrophage NOS (mNOS) is a type II NOS (NOS2). It is a Ca²⁺-independent protein, expressed in activated macrophages and some glial cells after stimulation. NOS2 is also present in several other cell types including hepatocytes, chondrocytes, endothelial cells and fibroblasts. The iNOS gene is mapped to human chromosome 17q11.2. iNOS is a dimeric flavoprotein with a heme group. It comprises the C-terminal reductase domain and an N-terminal oxygenase domain.

Anti-Nitric Oxide Synthase, Inducible antibody, Mouse monoclonal reacts specifically with inducible-type nitric oxide synthase (iNOS, also termed macNOS and mNOS). It does not react with NOS derived from brain (bNOS) or with endothelial-type NOS (eNOS). The antibody recognizes iNOS from human, mouse, rat and plant origin.

synthetic peptide corresponding to the C terminal region of nitric oxide synthase (NOS) of mouse macrophage origin (iNOS, also termed macNOS), conjugated to KLH

Anti-Nitric Oxide Synthase, Inducible antibody, Mouse monoclonal may be used:

• immunoblotting
• immunofluorescence
• immunohistochemistry
• fluorescence-activated cell sorting (FACS)

Inducible nitric oxide synthase (iNOS) or NOS2 catalyzes the oxidation of L-arginine to L-citrulline and nitric oxide (NO) via an OH-L-arginine intermediate in the presence of reduced nicotinamide adenine dinucleotide phosphate (NADPH) and oxygen. Elevated levels of iNOS is observed in asthma. A high level of iNOS leads to an increase in NO production which may contribute to cell death and tissue damage. It is also implicated in the pathophysiology of septic shock. Single nucleotide polymorphism in the iNOS gene is indicative of high risk for B and T-cell non-Hodgkin lymphoma. iNOS also elicits macrophage bactericidal functionality.

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

For continuous use, store at 2–8 ℃ for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilution samples should be discarded if not used within 12 hours.

Unless otherwise stated in our catalog, our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

12 - Non Combustible Liquids